Relay Therapeutics, Inc. (RLAY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 83 | 3 | 1 | 26 | 10 | 15 | 10 | 11 |
| Operating profit | $m | -303 | -310 | ||||||
| Net profit | $m | -52 | -364 | -291 | -342 | -338 | -276 | -286 | -274 |
| EPS reported | $ | -1.61 | -1.57 | ||||||
| Operating cashflow per share | $ | -1.37 | -1.05 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.37 | -1.05 | ||||||
| Free cash flow | $m | -236 | -212 | ||||||
| Net debt | $m | -555 | -911 | ||||||
| Book value equity | $m | 567 | 890 | ||||||
| Book value per share | $ | 3.30 | 4.39 | ||||||
| Number of shares | m | 171.59 | 202.85 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.56 | 1.63 | ||||||
| P/S LTM | x | 94.54 | 140.25 | ||||||
| P/FCF LTM | x | -6.15 | -6.84 | ||||||
| EV/EBITDA LTM | x | -5.13 | -4.88 | ||||||
| EV/Sales LTM | x | 91.18 | 411.75 | ||||||
| Earnings Yield LTM | % | -19.05% | -7.10% | ||||||
| FCF Yield | % | -16.25% | -14.62% | ||||||
| Quality | |||||||||
| ROE | % | -48.76% | -42.27% | ||||||
| ROIC | % | -50.50% | -33.72% | ||||||
| Operating margin | % | -19.72% | -29.99% | ||||||
| Gross margin | % | +76.83% | -5.67% | ||||||
| FCF/Sales | % | -1536.1% | -2050.3% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +53.44% | +3.43% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -7.27 | -6.92 | ||||||
| Net Debt/EBITDA | x | 0.19 | 0.32 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.98 | -1.02 | ||||||
| Gross debt/equity | x | 0.06 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free